{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:12:15Z","timestamp":1790647935151,"version":"4.1.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) may influence management and prognosis of atrial fibrillation (AF), but this relationship has been scarcely explored in contemporary global cohorts. We aimed to investigate the association between AF and COPD, in relation to treatment patterns and major outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>From the prospective, global GLORIA-AF registry, we analysed factors associated with COPD diagnosis, as well as treatment patterns and risk of major outcomes in relation to COPD. The primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACEs). A total of 36 263 patients (mean age 70.1 \u00b1 10.5 years, 45.2% females) were included; 2,261 (6.2%) had COPD. The prevalence of COPD was lower in Asia and higher in North America. Age, female sex, smoking, body mass index, and cardiovascular comorbidities were associated with the presence of COPD. Chronic obstructive pulmonary disease was associated with higher use of oral anticoagulant (OAC) [adjusted odds ratio (aOR) and 95% confidence interval (CI): 1.29 (1.13\u20131.47)] and higher OAC discontinuation [adjusted hazard ratio (aHR) and 95% CI: 1.12 (1.01\u20131.25)]. Chronic obstructive pulmonary disease was associated with less use of beta-blocker [aOR (95% CI): 0.79 (0.72\u20130.87)], amiodarone and propafenone, and higher use of digoxin and verapamil\/diltiazem. Patients with COPD had a higher hazard of primary composite outcome [aHR (95% CI): 1.78 (1.58\u20132.00)]; no interaction was observed regarding beta-blocker use. Chronic obstructive pulmonary disease was also associated with all-cause death [aHR (95% CI): 2.01 (1.77\u20132.28)], MACEs [aHR (95% CI): 1.41 (1.18\u20131.68)], and major bleeding [aHR (95% CI): 1.48 (1.16\u20131.88)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In AF patients, COPD was associated with differences in OAC treatment and use of other drugs; Patients with AF and COPD had worse outcomes, including higher mortality, MACE, and major bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euae021","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T07:31:12Z","timestamp":1705995072000},"source":"Crossref","is-referenced-by-count":31,"title":["Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3788-8942","authenticated-orcid":false,"given":"Giulio Francesco","family":"Romiti","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"},{"name":"Department of Translational and Precision Medicine, Sapienza \u2013 University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-4435","authenticated-orcid":false,"given":"Bernadette","family":"Corica","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"},{"name":"Department of Translational and Precision Medicine, Sapienza \u2013 University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6345-3742","authenticated-orcid":false,"given":"Davide Antonio","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza \u2013 University of Rome , Rome , Italy"},{"name":"Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-6502","authenticated-orcid":false,"given":"Frederick","family":"Frost","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-1800","authenticated-orcid":false,"given":"Arnaud","family":"Bisson","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"},{"name":"Service de Cardiologie, Centre Hospitalier R\u00e9gional Universitaire et Faculte\u0301 de Me\u0301decine de Tours , Tours , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-6234","authenticated-orcid":false,"given":"Tommaso","family":"Bucci","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"},{"name":"Department of General Surgery and Surgical Specialties \u2018Paride Stefanini\u2019, Sapienza \u2013 University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-045X","authenticated-orcid":false,"given":"Brian","family":"Olshansky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Iowa , Iowa City , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6587-3094","authenticated-orcid":false,"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital , Taipei , Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang Ming Chiao Tung University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-5348","authenticated-orcid":false,"given":"Menno V","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-2478","authenticated-orcid":false,"given":"Marco","family":"Proietti","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan , Italy"},{"name":"Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"},{"name":"Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University , Aalborg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"2024013008574598100_euae021-B1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/eurheartj\/ehaa822","article-title":"Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective","volume":"42","author":"Simons","year":"2021","journal-title":"Eur Heart J"},{"key":"2024013008574598100_euae021-B2","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1093\/eurheartj\/ehab453","article-title":"Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients","volume":"42","author":"Romiti","year":"2021","journal-title":"Eur Heart J"},{"key":"2024013008574598100_euae021-B3","first-page":"100386","article-title":"Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3.4 million individuals","volume":"17","author":"Wu","year":"2022","journal-title":"Lancet Reg Health\u2014Eur"},{"key":"2024013008574598100_euae021-B4","doi-asserted-by":"crossref","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990\u20132019: results from the Global Burden of Disease Study 2019","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"2024013008574598100_euae021-B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"2024013008574598100_euae021-B6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/dtb.2011.01.0003","article-title":"Can beta-blockers be used for people with COPD?","volume":"49","year":"2011","journal-title":"Drug Ther Bull"},{"key":"2024013008574598100_euae021-B7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/thoraxjnl-2016-208412","article-title":"\u03b2-Blockers, heart disease and COPD: current controversies and uncertainties","volume":"72","author":"Baker","year":"2017","journal-title":"Thorax"},{"key":"2024013008574598100_euae021-B8","first-page":"215","article-title":"Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD)","volume":"2","author":"van Gestel","year":"2010","journal-title":"J Thorac Dis"},{"key":"2024013008574598100_euae021-B9","doi-asserted-by":"crossref","first-page":"1121102","DOI":"10.3389\/fcvm.2023.1121102","article-title":"Combining bioinformatics and machine learning to identify common mechanisms and biomarkers of chronic obstructive pulmonary disease and atrial fibrillation","volume":"10","author":"Sun","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2024013008574598100_euae021-B10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijcard.2018.10.075","article-title":"Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms","volume":"276","author":"Matarese","year":"2019","journal-title":"Int J Cardiol"},{"key":"2024013008574598100_euae021-B11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.chest.2018.09.011","article-title":"A simple clinical risk score (C 2 HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects","volume":"155","author":"Li","year":"2019","journal-title":"Chest"},{"key":"2024013008574598100_euae021-B12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jacc.2009.11.040","article-title":"Progression from paroxysmal to persistent atrial fibrillation","volume":"55","author":"de Vos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024013008574598100_euae021-B13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1540-8167.2012.02448.x","article-title":"Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation","volume":"24","author":"Gu","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024013008574598100_euae021-B14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00392-022-01996-2","article-title":"Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF registry","volume":"111","author":"Lip","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"2024013008574598100_euae021-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-021-01957-1","article-title":"Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry","volume":"111","author":"Huisman","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"2024013008574598100_euae021-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","article-title":"Design and rationale of global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation","volume":"167","author":"Huisman M","year":"2014","journal-title":"Am Heart J"},{"key":"2024013008574598100_euae021-B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2019.08.012","article-title":"Safety and effectiveness of dabigatran at 2 years: final outcomes from Phase II of the GLORIA-AF registry program","volume":"218","author":"Mazurek","year":"2019","journal-title":"Am Heart J"},{"key":"2024013008574598100_euae021-B18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2019.10.047","article-title":"Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry","volume":"125","author":"Paquette","year":"2020","journal-title":"Am J Cardiol"},{"key":"2024013008574598100_euae021-B19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/europace\/eux301","article-title":"Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) long-term general registry","volume":"20","author":"Boriani","year":"2018","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B20","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1161\/STROKEAHA.118.021396","article-title":"Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events","volume":"49","author":"Ogawa","year":"2018","journal-title":"Stroke"},{"key":"2024013008574598100_euae021-B21","doi-asserted-by":"crossref","first-page":"e001478","DOI":"10.1136\/bmjresp-2022-001478","article-title":"Undiagnosed and \u2018overdiagnosed\u2019 COPD using postbronchodilator spirometry in primary healthcare settings: a systematic review and meta-analysis","volume":"10","author":"Perret","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2024013008574598100_euae021-B22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1164\/rccm.201804-0621CI","article-title":"Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease","volume":"198","author":"Diab","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024013008574598100_euae021-B23","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry Phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024013008574598100_euae021-B24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12916-022-02526-7","article-title":"Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF general long-term registry","volume":"20","author":"Romiti","year":"2022","journal-title":"BMC Med"},{"key":"2024013008574598100_euae021-B25","doi-asserted-by":"crossref","first-page":"f329","DOI":"10.1093\/europace\/eux322","article-title":"Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort","volume":"20","author":"Jani","year":"2018","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B26","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","article-title":"Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use","volume":"94","author":"Proietti","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2024013008574598100_euae021-B27","doi-asserted-by":"crossref","first-page":"210041","DOI":"10.1183\/16000617.0041-2021","article-title":"Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care","volume":"30","author":"Burke","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2024013008574598100_euae021-B28","doi-asserted-by":"crossref","first-page":"e030565","DOI":"10.1161\/JAHA.123.030565","article-title":"Implications of clinical risk phenotypes on the management and natural history of atrial fibrillation: a report from the GLORIA-AF","volume":"12","author":"Romiti","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2024013008574598100_euae021-B29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijcard.2015.09.062","article-title":"Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"202","author":"Durheim","year":"2016","journal-title":"Int J Cardiol"},{"key":"2024013008574598100_euae021-B30","doi-asserted-by":"crossref","first-page":"ehab724.0289","DOI":"10.1093\/eurheartj\/ehab724.0289","article-title":"Beta-blocker treatment in atrial fibrillation with chronic obstructive pulmonary disease: a danish nationwide study from 1995 to 2015","volume":"42","author":"Benson","year":"2021","journal-title":"Eur Heart J"},{"key":"2024013008574598100_euae021-B31","doi-asserted-by":"crossref","first-page":"20230864","DOI":"10.1515\/med-2023-0864","article-title":"Prescribing patterns in patients with chronic obstructive pulmonary disease and atrial fibrillation","volume":"18","author":"Liao","year":"2023","journal-title":"Open Med (Wars)"},{"key":"2024013008574598100_euae021-B32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/europace\/euab200","article-title":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial","volume":"24","author":"Metzner","year":"2022","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2024013008574598100_euae021-B34","doi-asserted-by":"crossref","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal","volume":"25","author":"Lip","year":"2023","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/europace\/euac225","article-title":"Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study","volume":"25","author":"T\u00f8nnesen","year":"2023","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10840-022-01328-4","article-title":"A new scoring system: PAT2C2H score. Its clinical use and comparison with HATCH and CHA2DS2-VASc scores in predicting arrhythmia recurrence after cryoballoon ablation of paroxysmal atrial fibrillation","volume":"65","author":"Cay","year":"2022","journal-title":"J Interv Card Electrophysiol"},{"key":"2024013008574598100_euae021-B37","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/europace\/eur406","article-title":"Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey","volume":"14","author":"Pisters","year":"2012","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B38","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.19102\/icrm.2022.130806","article-title":"Impact of chronic obstructive pulmonary disease on atrial fibrillation ablation outcomes according to the national readmission database","volume":"13","author":"Maraey","year":"2022","journal-title":"J Innov Card Rhythm Manag"},{"key":"2024013008574598100_euae021-B39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/europace\/euaa041","article-title":"Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models","volume":"22","author":"Dretzke","year":"2020","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2011.04.024","article-title":"Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone","volume":"108","author":"Jackevicius","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024013008574598100_euae021-B41","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/europace\/euv195","article-title":"Propafenone shows class Ic and class II antiarrhythmic effects","volume":"18","author":"Stoschitzky","year":"2016","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/heartjnl-2016-309458","article-title":"Underuse of \u03b2-blockers in heart failure and chronic obstructive pulmonary disease","volume":"102","author":"Lipworth","year":"2016","journal-title":"Heart"},{"key":"2024013008574598100_euae021-B43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ihj.2018.11.009","article-title":"Influence of atrial fibrillation on cardiac prognosis in chronic obstructive pulmonary disease","volume":"71","author":"Tomioka","year":"2019","journal-title":"Indian Heart J"},{"key":"2024013008574598100_euae021-B44","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1093\/eurheartj\/ehaa793","article-title":"Association of \u03b2-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis","volume":"41","author":"Yang","year":"2020","journal-title":"Eur Heart J"},{"key":"2024013008574598100_euae021-B45","doi-asserted-by":"crossref","first-page":"e001854","DOI":"10.1136\/bmjresp-2023-001854","article-title":"Beta-blockers reduce severe exacerbation in patients with mild chronic obstructive pulmonary disease with atrial fibrillation: a population-based cohort study","volume":"10","author":"Lin","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2024013008574598100_euae021-B46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/COPD.S174443","article-title":"A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population","volume":"14","author":"Rodr\u00edguez-Ma\u00f1ero","year":"2019","journal-title":"Int J COPD"},{"key":"2024013008574598100_euae021-B47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.hrtlng.2021.09.001","article-title":"A systematic literature review and meta-analysis on the impact of COPD on atrial fibrillation patient outcome","volume":"51","author":"Ye","year":"2022","journal-title":"Heart Lung"},{"key":"2024013008574598100_euae021-B48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2016.08.011","article-title":"Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) general registry","volume":"181","author":"Proietti","year":"2016","journal-title":"Am Heart J"},{"key":"2024013008574598100_euae021-B49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jjcc.2016.12.013","article-title":"Chronic obstructive pulmonary disease and atrial fibrillation: an unknown relationship","volume":"69","author":"Goudis","year":"2017","journal-title":"J Cardiol"},{"key":"2024013008574598100_euae021-B50","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/thoraxjnl-2012-202103","article-title":"The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease","volume":"67","author":"Steer","year":"2012","journal-title":"Thorax"},{"key":"2024013008574598100_euae021-B51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12890-023-02454-z","article-title":"Prevalence and clinical impact of frailty in COPD: a systematic review and meta-analysis","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2024013008574598100_euae021-B52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ccm.2020.06.002","article-title":"Multimorbidity in patients with chronic obstructive pulmonary disease","volume":"41","author":"Divo","year":"2020","journal-title":"Clin Chest Med"},{"key":"2024013008574598100_euae021-B53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12890-018-0573-0","article-title":"Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study","volume":"18","author":"Johansson","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2024013008574598100_euae021-B54","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2024013008574598100_euae021-B55","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","article-title":"Mobile health technology to improve care for patients with atrial fibrillation","volume":"75","author":"Guo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024013008574598100_euae021-B56","doi-asserted-by":"crossref","first-page":"101757","DOI":"10.1016\/j.eclinm.2022.101757","article-title":"Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: a post-hoc analysis from the prospective GLORIA-AF registry","volume":"55","author":"Romiti","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024013008574598100_euae021-B57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u2018Atrial Fibrillation Better Care\u2019 pathway in patients with atrial fibrillation: impact on clinical outcomes\u2014a systematic review and meta-analysis of 285,000 patients","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024013008574598100_euae021-B58","doi-asserted-by":"crossref","first-page":"e13498","DOI":"10.1111\/eci.13498","article-title":"Integrated care and outcomes in patients with atrial fibrillation and comorbidities","volume":"51","author":"Proietti","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2024013008574598100_euae021-B59","doi-asserted-by":"crossref","first-page":"2140071","DOI":"10.1001\/jamanetworkopen.2021.40071","article-title":"The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial","volume":"4","author":"Yao","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024013008574598100_euae021-B60","doi-asserted-by":"crossref","first-page":"e014932","DOI":"10.1161\/JAHA.119.014932","article-title":"Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial","volume":"9","author":"Proietti","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024013008574598100_euae021-B61","doi-asserted-by":"crossref","first-page":"24319","DOI":"10.1161\/JAHA.121.024319","article-title":"Effects of the Atrial Fibrillation Better Care pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy: a report from the ChiOTEAF registry","volume":"11","author":"Kotalczyk","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024013008574598100_euae021-B62","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/jama.2020.4437","article-title":"Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries","volume":"323","author":"Lindenauer","year":"2020","journal-title":"JAMA"},{"key":"2024013008574598100_euae021-B63","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-142-4-200502150-00005","article-title":"The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial","volume":"142","author":"Anthonisen","year":"2005","journal-title":"Ann Intern Med"},{"key":"2024013008574598100_euae021-B64","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa030287","article-title":"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","volume":"348","author":"Fishman","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013008574598100_euae021-B65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-93-3-391","article-title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial","volume":"93","author":"Kvale","year":"1980","journal-title":"Ann Intern Med"},{"key":"2024013008574598100_euae021-B66","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024013008574598100_euae021-B67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"2024013008574598100_euae021-B68","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1164\/rccm.202304-0691LE","article-title":"Cardiovascular disease and chronic obstructive pulmonary disease: adding a third dimension to the ABE global initiative for chronic obstructive lung disease 2023 chronic obstructive pulmonary disease classification","volume":"208","author":"Kostikas","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024013008574598100_euae021-B69","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024013008574598100_euae021-B70","first-page":"20","article-title":"2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2021","journal-title":"Thromb Haemost"},{"key":"2024013008574598100_euae021-B71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/euac153","article-title":"Contemporary management of atrial fibrillation in primary and secondary care in the UK: the prospective long-term AF-GEN-UK registry","volume":"25","author":"Shantsila","year":"2023","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B72","doi-asserted-by":"crossref","first-page":"e000110","DOI":"10.1161\/JAHA.113.000110","article-title":"Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry","volume":"2","author":"Fosbol","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2024013008574598100_euae021-B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/europace\/euad193","article-title":"Implementation of a screening and management pathway for chronic obstructive pulmonary disease in patients with atrial fibrillation","volume":"25","author":"Van Der Velden","year":"2023","journal-title":"Europace"},{"key":"2024013008574598100_euae021-B74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.09.056","article-title":"Chronic obstructive pulmonary disease and the development of atrial fibrillation","volume":"276","author":"Grymonprez","year":"2019","journal-title":"Int J Cardiol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euae021\/56397794\/euae021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/1\/euae021\/56451916\/euae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/1\/euae021\/56451916\/euae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T03:58:38Z","timestamp":1706587118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euae021\/7587624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euae021","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,28]]},"article-number":"euae021"}}